Have you ever felt like finding the right clinical trial is as complex as online dating, but without the fun swiping? At pRxEngage, we are revolutionising how patients and pioneering research connect, making the process as intuitive and empowering as finding your perfect match! The current scene in clinical trials is often slow, incredibly expensive, and frankly, fails both sponsors and the very patients it aims to help. While over 80% of patients are eager to join trials, a mere 30% actually do. This massive disconnect means trials are frequently delayed, racking up costs of £420,000 to over £6 million per day, and vital new drugs are stuck in development. We are here to change that. pRxEngage goes beyond simply recruiting; we’re about deep, sustained engagement. We look past just medical suitability to address whether a trial truly fits into a person’s life, helping them overcome any doubts. By making patients active ‘consumers’ of the trial, opting in at each stage, we build an ever-deepening relationship. The outcome? Better retention, greater adherence, and faster trial success. Our platform makes finding a trial as simple as swiping right or left. Our AI-powered system guides patients with easy-to-understand, jargon-free information and tools based on behavioural science, like Self-Determination Theory, to help them assess their suitability. Then, it seamlessly connects them directly to trial sites. For sponsors and sites, we provide real-time data dashboards and predictive analytics to identify suitable participants and improve retention. Our AI even helps streamline trial setup by parsing documents and generating clear summaries for participants. pRxEngage is engineered to redefine the connection between high-potential patients and appropriate clinical trials, accelerating crucial enrolment timelines. We foster sustained participant engagement, moving beyond conventional recruitment metrics to cultivate a more committed and informed cohort from the outset. This results in a higher-calibre, more dedicated participant pool from the initial stages, directly contributing to improved trial success rates, enhanced participant retention, and greater adherence to study protocols. We are truly unique because we combine community partnerships, predictive engagement, and operational support. We work with patients, sites, sponsors, charities, and patient organisations, building trust and integrating feedback. Our predictive tools identify engaged participants, and our operational support offers workflow and triage tools for sites and sponsors to boost efficiency. We are an additive solution, meaning we work alongside existing sponsor tools, making adoption easy. We are proud to be developing groups of community partners and ambassadors. This includes fantastic organisations like PiCC Unite, The PBC Foundation, and Don’tBePatient, with several more in advanced development. These collaborations are crucial to our mission of broadening awareness and access to research opportunities, ensuring that value and information remain within these communities. Our success springs from our visionary leadership and proven execution. Our Founder and CEO, Keith Berelowitz, brings over two decades of experience, having brought 12 drugs to market and achieved top-enrolling site status in numerous multi-centre trials. Charlie Myrick, our CTO, is a founding CTO with a background in architecting global engineering solutions and building HIPAA-certified SaaS patient tracking systems. Ethan Graff-Radford, our Head of Product, has experience in product management at an A16Z-backed company and has implemented agile methodologies for health-tech solutions. Our board members, David Guthrie and Daniel Graff-Radford, bring decades of experience shaping health-tech, scaling companies, and providing strategic technological oversight. This combined expertise means pRxEngage represents the convergence of profound clinical trial operational knowledge with sophisticated technological execution. Our intellectual property strategy focuses on our registered trademark for the pRxEngage brand, which is crucial for establishing our identity as we turn clinical trial interest into action. Beyond branding, we rely significantly on trade secrets to protect our unique algorithms, data analytics methodologies, behavioural science integration, and operational workflows. These elements fundamentally change the focus from mere recruiting to long-term patient engagement, retention, and measurable return on investment. Want to learn more about how pRxEngage is changing the game for clinical trials? Check out our company one-pager (https://docsend.com/v/y95hx/swiperightonresearch) and read our recent blog (https://docsend.com/v/y95hx/makingpatientfirstmeansomethingbeyondconsent) post to see our thinking in action. #pRxEngaged #GetpRxEngaged #ClinicalTrials #PatientEngagement #HealthcareInnovation #MedTech #ClinicalResearch
PatSnap
Patsnap empowers IP and R&D teams by providing better answers, so they can make faster decisions with more confidence. Founded in 2007, Patsnap is the global leader in AI-powered IP and R&D intelligence. Our domain-specific LLM, trained on our extensive proprietary innovation data, pairs seamlessly with our AI assistant, Hiro, to deliver insights that drive results—boosting IP productivity by 75% and cutting R&D wastage by 25%. IP and R&D teams collaborate better with a user-friendly platform across the entire innovation lifecycle. Over 15,000 companies trust Patsnap to innovate faster with AI, including NASA, PayPal, Sanofi, Dow Chemical, and Wilson Sonsini. | Founded in Singapore in 2007, PatSnap is a global leading innovation intelligence company. Leveraging domain-specific AI agents and robust analytics tools, PatSnap empowers IP and R&D teams to unlock insights, accelerate discoveries and protect breakthroughs. Trusted by more than 15,000 enterprises, law firms and research institutions in over 50 countries including one-third of the world’s largest R&D spenders, Patsnap transforms how organizations innovate and make critical decisions. Learn more at www.patsnap.com.
Parque Pharma / Helix
PARQUE PHARMA + HELIX Where Infrastructure Meets Execution In life sciences, speed, compliance, and control often conflict. Companies must choose: build and wait years, outsource and lose visibility, or buy risk. These tradeoffs drain capital, erode margin, and delay impact. Parque Pharma and Helix eliminate that tradeoff. We offer a single-entry platform into Mexico and Latin America—combining GMP-ready infrastructure and regulatory-commercial execution in one seamless model. Two Forces. One Outcome. Parque Pharma Mexico’s first and only pharmaceutical condominium model, delivering turnkey, validated GMP facilities with shared infrastructure. No CapEx. No permitting delays. Just speed, certainty, and full regulatory alignment (COFEPRIS, FDA, EMA, USDA). Helix A strategic execution system for health, designed to compress timelines and reduce friction. From product registration to facility activation and market expansion, Helix integrates regulation, operations, and commercial logic. Together, we make GMP execution plug-and-play. What We Offer GMP facility leasing (with option to buy) COFEPRIS / FDA / EMA regulatory navigation Product registration and local compliance GMP validation & audit readiness Licensing, M&A support, and market launch Operational strategy for long-term scaling Why It Works Speed to Market Installations ready in 10 months or less—with fast-track validation pathways. Regulatory Clarity Certified cleanrooms. No licensing delays. No retrofit risk. Zero CapEx, Maximum Flexibility Lease Class A, spec-built facilities designed for pharma, biotech, supplements, and veterinary use. Execution Certainty Validated systems. Turnkey delivery. Compliance built-in. Ideal For… Biotech companies expanding into Latin America Pharma looking to escape CMO bottlenecks Brands needing dual COFEPRIS + SENASICA certification Supplement companies requiring FDA-grade local ops CDMOs seeking flexible GMP-certified space Let’s Connect at BIO 2025 If you’re scaling in Mexico or LatAm— Let’s turn compliance and construction into momentum.
Orientation Marketing
Specialist Marketing Agency for the Pharmaceutical and Life Science Sectors Orientation Marketing is a life science and pharmaceutical marketing agency operating within specialist B2B scientific sectors. We help drug, ingredients, packaging, medical technology, contract manufacturing, development and research organisations uncover marketing opportunities to become visible, increase engagement and generate more leads.
OOHO
Ooho is the life sciences marketing agency that blends scientists with marketing experts. We help companies build brands, launch products, and generate demand in complex markets. Trusted by 70+ clients globally, with a presence across Europe and North America.
NUERNBERGMESSE BRASIL FEIRAS E CONGRESSOS LTDA
NürnbergMesse Brasil is one of the 10 largest event and exhibition organizers in the country. A subsidiary of the NürnbergMesse Group, founded in 1974 in Germany, the company arrived in Brazil in 2009 and quickly established itself in the market. The promoter stands out for the quality of the services and innovations presented at the fairs it organizes. It always brings together a qualified audience, both national and international. Currently, NürnbergMesse Brasil is responsible for the most important business meetings in Latin America, where it brings together suppliers, distributors and resellers from various segments of the economy. The company’s purpose is precisely to help develop the national industry and increase Brazil’s relevance in the foreign market. Therefore, more than presenting solutions, the company promotes experiences, always with the aim of making the participation of exhibitors and visitors unforgettable, in addition to bringing information and knowledge to everyone. Among the main events organized are Expo Revestir, Haus Decor Show, PET South America, PET VET, FCE Pharma, FCE Cosmetique, Analitica Latin America, Glass South America, ABRAFATI SHOW, Catarina Aviation Show and Brazilian Footwear Show.
Nucleon Research Pvt Ltd
Nucleon Research, a leading global Clinical Research Organization (CRO) headquartered in the United States with active operations across India and Southeast Asia, is keen to explore potential strategic collaborations with your organization. We specialize in comprehensive clinical research services, including: Clinical Trials (Phases I–IV, Real-World Evidence & Investigator-Initiated Trials) Clinical Supplies & Packaging Clinical Manufacturing Standalone CDMO Services We believe our aligned visions present a unique opportunity to create significant mutual value through collaboration in clinical research initiatives across the USA, India, or Southeast Asia. We would welcome the opportunity to discuss how we might collaborate on upcoming clinical research initiatives. Contact @ BD@nucleonresearch.com
New Genesis
New Genesis (www.newgenesis.cl) is a business consultancy with 18 years of experience, founded in Chile. We have extensive expertise across Latin America, USA, and the EU, with offices in Santiago de Chile and Mexico City. Our focus is on providing innovation management services and comprehensive technology transfer process development for private companies, institutions, and startups. We develop customized services tailored to the specific requirements and objectives of each of our clients for value generation and/or capture. Our offerings include IP and Market Assessments, Identification, Evaluation, and Valuation of Technologies, Startups, and Science-Based Companies. We also specialize in structuring and implementing capital raising processes, as well as managing projects for scaling and business consolidation, where the specific application of a technology is the focus of development. Additionally, we offer services in the design, implementation, and management of acceleration projects for R&D initiatives and startups. Finally, we have +10 years of real and successful experience in managing venture capital funds and investments in technological developments. Our motto is: “Turning ideas into great projects, aiming to generate extraordinary results.” | We drive business, innovation, and impact with purpose. At New Genesis, we connect companies, universities, and startups with strategic solutions and technologies with potential. We specialize in Business Strategy , Innovation, and Technology Transfer , with a presence in Chile, Mexico, and Latin America. We combine strategic analysis, digital tools, and industry expertise to support organizational transformation processes, project scaling, and the development of solutions with real impact.
Mediwhale Co Ltd.
Mediwhale is a company specializing in retinal AI biomarkers for predicting cardiovascular, renal, and metabolic risks. Our innovative technology enables a 30-second eye scan to accurately identify future risks of cardiovascular disease, chronic kidney disease, and existing ocular conditions, providing physicians and patients with actionable insights for preventive care. Mediwhale’s solutions are called “Dr. Noon” are already being utilized in clinical settings across South Korea, the EU, UK, Dubai, and other Asia regions, supported by regulatory approvals and a reimbursement code. Our technology is backed by robust clinical evidence, with key studies published in leading journals such as The Lancet Digital Health and European Heart Journal Digital Health. | Mediwhale leverages retinal imaging and AI to advance early detection, personalized risk assessment, and preventive care. Retinal AI enables the early identification of cardiometabolic risk, supporting proactive and preventive healthcare. Mediwhale offers the world’s first regulatory-approved AI solution for cardiovascular risk assessment using retinal imaging.
leap:up GmbH / biosaxony e.V.
leap:up GmbH (a partner of the German biotech association biosaxony) empowers founders, startups, and SMEs in the life sciences to take significant steps towards innovation, market entry, commercialization, and growth. Our vision: A sustainably healthier world. Our mission is to support scientists, companies and startups in the field of life sciences to transform their innovative ideas into scalable business models. Through our projects and world-class services, we help to bridge the gap between idea and realization. “leap:up” stands for bold leaps into the future of life sciences. As a life science enabler, we create optimal conditions for the realization of groundbreaking ideas. Our portfolio includes acceleration and development services for life science projects, regulatory support, training programs, and events through our in-house academy, as well as the provision of state-of-the-art co-working labs in Leipzig. We are actively expanding our international presence and service, including investor relations and funding opportunities. Our focus areas include diagnostics, cell and gene therapy, radiopharmacy, smart medical devices, robotics and AI, digital health, and phage therapy.